{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '11.2.9.', 'Pregnancy Testing', '75', '11.2.10.', 'HAE Diagnostic Confirmation', '75', '11.2.11.', 'Other Laboratory Assessments', '76', '11.2.12.', 'Pharmacokinetics and Pharmacodynamics', '76', '11.2.13.', 'Pharmacogenomic Testing', '76', '11.2.14.', 'Rash Assessment', '77', '11.2.15.', 'Adverse Events', '78', '11.3.', 'Patient-Reported Outcomes', '79', '11.4.', 'HAE Attack and Dosing Diary and Attack Confirmation', '79', '11.4.1.', 'Screening and Parts 1 and 2', '79', '11.4.1.1.', 'HAE Attack and Dosing Diary', '79', '11.4.1.2.', 'Investigator Confirmation of Attacks', '80', '11.4.1.3.', 'Scheduled Telephone Contact', '81', '11.4.2.', 'Part 3', '81', '11.4.2.1.', 'HAE Attack Diary', '81', '11.4.2.2.', 'Scheduled Telephone Contact', '82', '12.', 'ADVERSE EVENT MANAGEMENT AND REPORTING', '82', '12.1.', 'Adverse Events', '82', '12.1.1.', 'Definitions', '82', '12.1.1.1.', 'Adverse Event', '82', '12.1.1.2.', 'Serious Adverse Event', '83', '12.1.1.3.', 'Adverse Events of Special Interest', '84', '12.1.2.', 'Method, Frequency, and Time Period for Detecting Adverse Events and', 'Reporting Serious Adverse Events', '84', '12.1.3.', 'Definition of Severity', '85', '12.1.4.', 'Definition of Relationship to Study Drug', '86', '12.1.5.', 'Reporting Serious Adverse Events and Suspected Unexpected Serious', 'Adverse Reactions', '86', '12.1.5.1.', 'Reporting Events of Special Interest', '87', '12.1.6.', 'Pregnancy', '88', '12.1.7.', 'Serious Breaches of Good Clinical Practice', '88', '12.1.8.', 'Treatment Interruptions', '88', '12.1.9.', 'Emergency Procedures', '88', '19']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '12.2.', 'Toxicity Management', '89', '12.2.1.', 'Rash', '89', '12.2.1.1.', 'Study Drug Administration for Grade 1 or 2 Rashes Considered Related to', 'Study Drug', '89', '12.2.2.', 'Aminotransferase (ALT or AST) Elevation', '90', '12.2.3.', 'Overdose', '91', '12.3.', 'Data Monitoring Committee', '91', '13.', 'STATISTICS', '92', '13.1.', 'Hypotheses', '92', '13.2.', 'Sample Size Considerations', '92', '13.3.', 'Sample Size Re-estimation', '93', '13.4.', 'Stratification', '93', '13.5.', 'Statistical Methods', '93', '13.5.1.', 'Analysis Populations', '93', '13.5.1.1.', 'Screen Failures', '93', '13.5.1.2.', 'Intent-to-Trea Population', '93', '13.5.1.3.', 'Safety Population', '93', '13.5.1.4.', 'Per Protocol Population', '93', '13.5.1.5.', 'Completers Population', '94', '13.5.1.6.', 'Pharmacodynamic Population', '94', '13.5.1.7.', 'Pharmacokinetic/Pharmacodynamic Population', '94', '13.5.2.', 'General Considerations for Data Analysis', '94', '13.5.3.', 'Subject Demographic and Disposition Data', '94', '13.5.4.', 'Analysis of Efficacy Variables', '94', '13.5.4.1.', 'Primary Efficacy Analysis', '95', '13.5.4.2.', 'Secondary and Exploratory Efficacy Analyses', '95', '13.5.5.', 'Planned Analyses', '96', '13.5.6.', 'Analysis of Safety Variables', '97', '13.5.7.', 'Health Outcome Analyses', '98', '13.5.8.', 'Pharmacokinetic Analyses', '98', '13.5.9.', 'Pharmacodynamic Analyses', '98', '13.5.10.', 'Pharmacokinetic/Pharmacodynamic Analyses', '98', '14.', 'STUDY ADMINISTRATION', '98', '20']\n\n###\n\n", "completion": "END"}